Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

CAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on ou
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  CytRx Corporation (CYTR), a biopharmaceutical ... reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical ... in the early months of 2015, including the ... of aldoxorubicin in patients with soft tissue sarcoma, ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation ... its continued business momentum and long-term growth strategies at ... New York City . President and Chief ... unique opportunities the company has to bring forward meaningful ... growing markets and deliver shareholder value. ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... 05, 2007 /PRNewswire/ -- Results from,the primary ... study showed that 77 percent of treatment-experienced ... tablets with,100 mg ritonavir (PREZISTA/r) twice daily, ... (ARV) agents, reached a,plasma viral load of ...
... Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company specializing ... two Phase III clinical trials for its ... severe,seasonal allergic rhinitis, commonly known as hay ... in both placebo and,PreHistin-treated patient groups, thereby ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5
(Date:5/1/2015)... CA (PRWEB) May 01, 2015 TROY ... the Cerner Southeast Regional User Group (RUG) Conference in ... Cerner Southeast Regional User Group Conference provides a forum ... vendors who support all aspects of electronic medical record ... of Cerner software applications. , In addition to sponsoring ...
(Date:5/1/2015)... 01, 2015 Hope For The Warriors® ... Hope For The Warriors® and military families. All American ... Hope For The Warriors®, a national nonprofit dedicated to ... and restoring hope for our service members and our ... American Ford collected and matched small autograph fee from ...
(Date:5/1/2015)... The fields of genetics and genomics, the ... genes with one another and the environment, is rapidly ... LabRoots, the premier producer of interactive virtual events for ... its annual conference spotlighting the recent advances in Genetics ... Genomics 2015 , a two-day event presented entirely online ...
(Date:5/1/2015)... Washington, D.C. (PRWEB) May 01, 2015 Today ... campaign is expanding its fundraising efforts to help protect the ... the first new program support country added since Girl Up ... Day fundraising campaign aimed at supporting adolescent girls in the ... years Girl Up has supported the advancement of adolescent girls ...
(Date:5/1/2015)... 2015 Digital technology and Wi-Fi-enabled medical ... between prenatal appointments, a preliminary study has ... sample of low-risk pregnant women, will be presented as ... Medical Faculty Associates at the 2015 American Congress of ... May 2-6. The digital technology used was developed by ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3Health News:United Nations Foundation’s Girl Up Campaign Announces New Funding Initiative to Support Adolescent Girls in India 2Health News:United Nations Foundation’s Girl Up Campaign Announces New Funding Initiative to Support Adolescent Girls in India 3Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... The Duke Human Vaccine Institute today announced a ... Diagnostics to enable the rapid development of a ... pandemic virus threat such as pandemic influenza. The ... utilize resources of the National Institute of Allergy ...
... 14 (HealthDay News) -- Parents who say "um" and "uh" ... they,re actually helping the children learn language more efficiently, according ... 30 months found that older children paid more attention to ... the item stumbled and said, "Look at the, uh..." ...
... More intensive or family-based HIV prevention interventions may ... and stop engaging in risky sexual behavior, say researchers ... Juvenile offenders are at increased risk for contracting HIV ... have sex at earlier ages, have more sexual partners, ...
... 2011 An international consortium of scientists, including ... that the "one-size fits all" strategy of uniformly ... for patients with high on-treatment platelet reactivity does ... and stent thrombosis after percutaneous coronary intervention (PCI). ...
... French and Spanish . , A ... Antonio Campos and Miguel Alaminos (histologists), Mara del Mar Prez, ... the ophthalmologist Miguel Gonzlez Andrades, University Hospital San Cecilio, Granada, ... extracted pig corneal cells and replaced them with human stem ...
... , THURSDAY, April 14 (HealthDay News) -- Home safety ... small children, according to a new study. Researchers ... groups of families with newborns. One set of families ... homes, including stairway gates, cabinet locks, electrical outlet covers, ...
Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Better HIV prevention interventions needed for juvenile offenders 2Health News:Better HIV prevention interventions needed for juvenile offenders 3Health News:Antiplatelets: 1 person, 1 dose? 2Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: